Median Number of 131I Treatments, Median Administered Activity, and Median Cumulative Activity (GBq) According to Patient Group
| Group 1 (n = 106) | Group 2 (n = 114) | Group 3 (n = 132) | ||||
| Parameter | GR (n = 79) | MSKCC (n = 27) | GR (n = 74) | MSKCC (n = 40) | GR (n = 78) | MSKCC (n = 54) |
| 5-y OS | 0.96 (95% CI, 0.88–0.99) | 0.96 (95% CI, 0.73–0.99) | 0.92 (95% CI, 0.83–0.97) | 0.87 (95% CI, 0.71–0.94) | 0.70 (95% CI, 0.58–0.80) | 0.65 (95% CI, 0.50–0.77) |
| 131I treatment | ||||||
| Median number | 4 (1–14) | 2 (1–7) | 4 (1–14) | 3 (1–9) | 4 (1–13) | 3 (1–8) |
| Median administered activity (GBq) | 3.7 (1.4–5.2) | 7.5 (2.7–14.1) | 3.7 (1.1–8.7) | 8.9 (4.6–18.6) | 3.7 (1.8–11.1) | 10.6 (3.7–16.7) |
| Median cumulative activity (GBq) | 14.8 (3.7–39.2) | 17.2 (2.7–56.4) | 14.8 (2.2–52.5) | 23.1 (5.5–112) | 14.8 (1.8–52.5) | 29.8 (3.7–83.9) |
Group 1 = patients aged < 40 y with no visible disease on cross-sectional imaging, micronodular lung metastases or single bone lesion; group 2 = patients aged < 40 y with either macrometastases or patients aged > 40 y with micrometastases; group 3 = patients aged > 40 y with lung macrometastases or multiple bone metastases (8).
Data in parentheses are ranges unless otherwise indicated.